BioSpace News Archive

Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce that the Company has appointed Sandra Pennell as its new Senior Vice President of Finance.

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX) today reported initial proof of concept monotherapy data from its Phase 1 MYTHIC clinical trial evaluating lunresertib (RP-6306), a first-in-class, oral PKMYT1 inhibitor in molecularly selected advanced solid tumors.

Worksite Labs, Inc., a pioneering decentralized diagnostic testing company committed to expanding access to healthcare services, is proud to announce the appointment of two new board members, Roberta Luskin-Hawk, M.D. and Afsaneh Naimollah.

Geron Corporation announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to participate in a fireside chat in person at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA, on Thursday, June 15, 2023 at 8:40 a.m. PT.

Immune-Onc Therapeutics, Inc. announced Phase 1 data for IO-202, a first-in-class humanized IgG1 monoclonal antibody targeting Leukocyte Immunoglobulin-Like Receptor B4.

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”) today announces, in line with the Company’s Fix, Fund, Propel approach, details related to recently reported financial results for its first quarter ended March 31, 2023 and provides a business update.

RedShift BioAnalytics announced it was launching the HaLCon Analyzer, an advanced, fit-for-purpose, liquid chromatography platform designed to provide protein titer results equivalent to traditional protein A, HPLC with a faster, easier, and more cost-effective platform method.

ITabMed Ltd., a clinical-stage biotech company in China, announced the IND approval from China National Medical Products Administration for A-337, a CD3-activating bi-specific antibody targeting EpCAM.

Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces it will host a Key Opinion Leader webinar on Proof-of-Concept Phase 2a study preliminary results of SENS-401 for residual hearing preservation following cochlear implantation.

Vir Biotechnology, Inc. announced that five abstracts highlighting new data from the Company’s broad hepatitis portfolio addressing both hepatitis B virus and hepatitis D virus have been accepted for presentation at the annual meeting of the European Association for the Study of the Liver, EASL™ Congress 2023, taking place in Vienna from June 21-24.